Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · First Trust

First Trust Nasdaq Pharmaceuticals ETF (FTXH)

Ticker FTXH · Since 2016-09-20 · · Holdings as of Jun 30, 2026

Expense ratio
0.6%$60/yr per $10k
5-yr return
+6.5%annualized
1-yr return
+24.0%as of Dec 2025
Net assets
$36.2Mall share classes
Holdings
51

Bottom line

Is FTXH a good fund? The bottom line

FTXH is an actively managed health care sector ETF from First Trust.

Its expense ratio is 0.6% — about $60 a year on every $10,000 invested, cheaper than 77% of health care sector funds we track.

It returned +24.0% over one year, +6.5% a year over five years (as of Dec 31, 2025, per its prospectus).

With $36.2 million in net assets and 51 holdings, its largest position is Eli Lilly & Company (7.8%) and the top 10 make up 53.1% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 50% top-holdings overlap).

What stands out

  • Low cost: cheaper than 77% of health care sector peers
  • 5-year return beat 77% of category peers

What to watch

  • Concentrated: top 10 holdings are 53.1% of assets
  • Small fund ($36.2 million) — small funds are likelier to close

Updated Nov 19, 2026

What FTXH invests in

The First Trust Nasdaq Pharmaceuticals ETF (the Fund ) seeks investment results that correspond generally to the price and yield (before the Funds fees and expenses) of an equity index called the Nasdaq US Smart Pharmaceuticals TM Index (the Index ).

Under normal market conditions, the Fund will invest at least 80% of its net assets (plus any investment borrowings) in the securities that comprise the Index. The Fund, using an indexing investment approach, attempts to replicate, before fees and expenses, the performance of the Index. The Index is owned and is developed, maintained and sponsored by Nasdaq, Inc. (the Index Provider ). The Index Provider may, from time to time, exercise reasonable discretion as it deems appropriate in order to ensure Index integrity. According to the Index Provider, the Index is designed to provide exposure to the 30 to 50 top factor-ranked securities from U.S. pharmaceutical and biotechnology companies. The Indexs initial selection universe consists of the component securities of the Nasdaq US Benchmark TM Index that have been classified as comprising the pharmaceuticals and biotechnology subsectors…

From the fund's prospectus (filed Jul 29, 2026).

FTXH performance

Fund calendar-year total returns, 2017–2025 2017: +18.8%; 2018: −8.4%; 2019: +22.4%; 2020: +10.9%; 2021: +6.1%; 2022: +2.5%; 2023: −1.4%; 2024: +3.0%; 2025: +24.0% +19% 2017 −8% 2018 +22% 2019 +11% 2020 +6% 2021 +3% 2022 −1% 2023 +3% 2024 +24% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
FTXH+24.0%+6.5%—
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full FTXH performance history →

What FTXH costs

On a $10,000 investment, FTXH's 0.6% expense ratio costs about $60 a year. The median health care sector fund charges 0.96%.

See the full FTXH fee table →

FTXH top 10 holdings

#Holding% of fund
1Eli Lilly & Company LLY7.77%
2Abbvie Inc ABBV7.39%
3Merck & Company Inc MRK7.07%
4Johnson & Johnson JNJ6.96%
5Bristol-myers Squibb Company BMY6.29%
6Biogen Inc BIIB3.84%
7Viatris Inc VTRS3.62%
8Cardinal Health Inc CAH3.53%
9Vertex Pharmaceuticals Inc VRTX3.41%
10Amgen Inc AMGN3.18%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 53.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to FTXH

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%50% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%51% Compare
iSharesIYH iShares U.S. Healthcare ETF0.37%50% Compare

More funds like FTXH →

FTXH FAQ

What is the expense ratio of FTXH?
FTXH's expense ratio is 0.6%, which works out to about $60 a year for every $10,000 invested.
Is FTXH a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 77% of health care sector peers; 5-year return beat 77% of category peers; concentrated: top 10 holdings are 53.1% of assets; small fund ($36.2 million) — small funds are likelier to close. This is general information, not personalized advice.
What does FTXH hold?
FTXH's largest holdings are Eli Lilly & Company (7.8%), Abbvie Inc (7.4%), Merck & Company Inc (7.1%), Johnson & Johnson (7.0%), Bristol-myers Squibb Company (6.3%). It holds 51 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is FTXH's 5-year return?
FTXH returned +6.5% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
What is a cheaper alternative to FTXH?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 50% with FTXH and charges 0.08%.
Who manages FTXH?
FTXH is offered by First Trust through First Trust Exchange-traded Fund Vi.